Cargando…

Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Fagiani, Francesca, Catanzaro, Michele, Lanni, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445715/ https://www.ncbi.nlm.nih.gov/pubmed/32843617 http://dx.doi.org/10.1038/s41392-020-00287-4

Ejemplares similares

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2
por: Catanzaro, Michele, et al.
Publicado: (2020)

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
por: Yang, Yang, et al.
Publicado: (2021)

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
por: Wu, Nicholas C., et al.
Publicado: (2020)

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients
por: Yan, Qihong, et al.
Publicado: (2021)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2
por: Zhang, Qi, et al.
Publicado: (2021)

Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants
por: Yan, Qihong, et al.
Publicado: (2022)

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
por: Tian, Xiaolong, et al.
Publicado: (2022)

Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
por: Pushparaj, Pradeepa, et al.
Publicado: (2023)

SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes
por: Brewer, R. Camille, et al.
Publicado: (2022)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

Virtual Issue on SARS-CoV-2: Evolution of a Pandemic
por: McGrath, Casey
Publicado: (2023)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
por: Latorre, Daniela
Publicado: (2022)

Peripheral and systemic antigens elicit an expandable pool of resident memory CD8(+) T cells in the bone marrow
por: Pascutti, Maria Fernanda, et al.
Publicado: (2019)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

A two‐step infection model: From SARS‐CoV‐2 entry and trafficking to egress and spread
por: You, Liting, et al.
Publicado: (2023)

Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain
por: Tan, Timothy J.C., et al.
Publicado: (2021)

Antigen‐dependent multistep differentiation of T follicular helper cells and its role in SARS‐CoV‐2 infection and vaccination
por: Baumjohann, Dirk, et al.
Publicado: (2021)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines
por: Li, Maochen, et al.
Publicado: (2022)

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research
por: Häfner, Sophia Julia
Publicado: (2021)

How will previous infection or current vaccination strategies protect us from future SARS‐CoV‐2 variant infections?
por: Monteiro, Olivia
Publicado: (2022)

Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

Adapt or perish: SARS-CoV-2 antibody escape variants defined by deletions in the Spike N-terminal Domain
por: Ribes, Marta, et al.
Publicado: (2021)

Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
por: Bosch, Francesc, et al.
Publicado: (2021)

SARS attacks!()
por: Häfner, Sophia
Publicado: (2013)

Development of Antibody‐Directed Therapies: Quo Vadis?
por: Rodrigues, Tiago, et al.
Publicado: (2018)

SARS-CoV-2 sensory loss
por: York, Ashley
Publicado: (2022)

Sewer biofilms and SARS-CoV-2
por: Du Toit, Andrea
Publicado: (2023)

SURFing SARS-CoV-2 inhibition
por: Taglialegna, Agustina
Publicado: (2023)

Unraveling the Dynamics of Antibody-Antigen Interaction by DNA Origami
por: Nie, Zhou
Publicado: (2020)

A CNS gateway for SARS-CoV-2
por: Yates, Darran
Publicado: (2021)

SARS-CoV-2 detected in olfactory neurons
por: Lemprière, Sarah
Publicado: (2021)

Super(antigen) target for SARS-CoV-2
por: Brown, Matthew, et al.
Publicado: (2021)

Cellular basis for SARS-CoV-2 infection
por: Baumann, Kim
Publicado: (2020)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rcu4i3hia3pvj6urgeqfiithr9